Skandinaviska Enskilda Banken AB publ Has $10.77 Million Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Skandinaviska Enskilda Banken AB publ lifted its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 492.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 205,167 shares of the company's stock after acquiring an additional 170,520 shares during the period. Skandinaviska Enskilda Banken AB publ owned approximately 0.39% of Janux Therapeutics worth $10,771,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of JANX. Victory Capital Management Inc. increased its stake in Janux Therapeutics by 143.4% during the 3rd quarter. Victory Capital Management Inc. now owns 29,745 shares of the company's stock worth $1,351,000 after purchasing an additional 17,525 shares in the last quarter. Plato Investment Management Ltd increased its stake in Janux Therapeutics by 18.7% during the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company's stock worth $54,000 after purchasing an additional 187 shares in the last quarter. Intech Investment Management LLC bought a new stake in Janux Therapeutics during the 3rd quarter worth approximately $368,000. Charles Schwab Investment Management Inc. increased its stake in Janux Therapeutics by 202.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company's stock worth $10,639,000 after purchasing an additional 156,675 shares in the last quarter. Finally, Algert Global LLC bought a new stake in Janux Therapeutics during the 3rd quarter worth approximately $1,112,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 13,334 shares of Janux Therapeutics stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total transaction of $731,769.92. Following the completion of the sale, the insider now owns 82,139 shares of the company's stock, valued at approximately $4,507,788.32. This trade represents a 13.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $56.19, for a total value of $1,404,750.00. Following the sale, the chief executive officer now directly owns 217,054 shares of the company's stock, valued at $12,196,264.26. This represents a 10.33 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 50,002 shares of company stock valued at $2,684,703 in the last quarter. 29.40% of the stock is currently owned by insiders.

Janux Therapeutics Stock Down 0.1 %

Shares of NASDAQ:JANX traded down $0.02 during midday trading on Wednesday, hitting $30.91. The stock had a trading volume of 708,988 shares, compared to its average volume of 821,492. The business's 50-day simple moving average is $38.03 and its 200-day simple moving average is $46.78. Janux Therapeutics, Inc. has a 12 month low of $28.92 and a 12 month high of $71.71. The company has a market cap of $1.83 billion, a P/E ratio of -26.42 and a beta of 3.23.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, equities analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on JANX shares. HC Wainwright reissued a "buy" rating and set a $70.00 target price on shares of Janux Therapeutics in a research note on Monday, March 3rd. Leerink Partners increased their target price on Janux Therapeutics from $79.00 to $91.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 3rd. Leerink Partnrs raised shares of Janux Therapeutics to a "strong-buy" rating in a research note on Friday, November 22nd. Wedbush reaffirmed an "outperform" rating and set a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Finally, Stifel Nicolaus raised their target price on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a "buy" rating in a research note on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Janux Therapeutics presently has a consensus rating of "Buy" and an average target price of $92.44.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.